Venture firms suffered fundraising woes last year, and a handful of biopharma funds stopped investing. It could get worse.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.
Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.
The UK government is making it easier for millions of people to participate in clinical trials and is boosting transparency around how studies are delivered across the National Health Service.
